Secondary Logo

Institutional members access full text with Ovid®


Sacconi, Riccardo, MD, FEBO*; Cohen, Salomon Yves, MD, PhD; Borrelli, Enrico, MD, FEBO*; Bandello, Francesco, MD, FEBO*; Souied, Eric H., MD, PhD; Querques, Giuseppe, MD, PhD*

doi: 10.1097/IAE.0000000000002567
Correspondence: PDF Only

*Department of Ophthalmology, IRCCS Ospedale San Raffaele, University Vita-Salute, Milan, Italy

Department of Ophthalmology, Hospital Intercommunal de Creteil, University Paris Est Creteil, Creteil, France

F. Bandello is a consultant for: Alcon (Fort Worth, Texas), Alimera Sciences (Alpharetta, Georgia), Allergan Inc (Irvine, California), Farmila-Thea (Clermont-Ferrand, France), Bayer Schering-Pharma (Berlin, Germany), Bausch and Lomb (Rochester, New York), Genentech (San Francisco, California), Hoffmann-La-Roche (Basel, Switzerland), Novagali Pharma (Évry, France), Novartis (Basel, Switzerland), Sanofi-Aventis (Paris, France), Thrombogenics (Heverlee, Belgium), and Zeiss (Dublin). E. H. Souied is a consultant for Allergan Inc (Irvine, California), Bausch and Lomb (Rochester, New York), Bayer Schering-Pharma (Berlin, Germany), and Novartis (Basel, Switzerland). G. Querques is a consultant for Alimera Sciences (Alpharetta, Georgia), Allergan Inc (Irvine, California), Bayer Schering-Pharma (Berlin, Germany), Heidelberg (Germany), Novartis (Basel, Switzerland), Sandoz (Berlin, Germany), and Zeiss (Dublin). The remaining authors have no conflicts of interests to disclose.

© 2019 by Ophthalmic Communications Society, Inc.